RecruitingPhase 3NCT05995353
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Sponsor: AbbVie
Minneapolis, MN · +10 more sites